Nuclear Receptors, Drug Discovery, Nutraceuticals, and Neurodegenerative Diseases
A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cell Nuclei: Function, Transport and Receptors".
Deadline for manuscript submissions: 25 October 2026 | Viewed by 90
Special Issue Editors
Interests: nuclear receptors; drug discovery; neurodegenerative diseases
Interests: nuclear receptors; NAFLD; NASH; metabolic disease; inflammation; drug discovery; pharmacology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Nuclear receptors (NRs) are pivotal regulators of cellular metabolism and inflammation, with profound implications for metabolic dysfunction-associated diseases. This Special Issue focuses on cutting-edge research leveraging NR modulation—including PPARs, LXR-s and REVERB, NURR1 and TLX—to develop novel therapeutics based on small molecules or nutraceuticals for neurodegenerative diseases, including Alzheimer’s disease, frontal temporal dementia, and other diseases, including MAFLD-NASH and cardiometabolic disorders. We welcome original articles and reviews exploring NR-targeted drug design (e.g., machine-learning-driven libraries, in silico development), delivery systems (nanoparticles, ligand-targeted constructs), and mechanistic insights from multi-omics, single-cell analysis, and preclinical models. This issue aims to integrate translational research and basic science, providing a resource for advancing NR-based therapies and deepening the understanding of metabolic–inflammatory networks.
Prof. Dr. Rajesh Haresh Amin
Dr. Kristine Griffett
Dr. Meenakshi Singh
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- nuclear receptors
- neurodegenerative diseases
- metabolic dysfunction
- inflammation
- drug design
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
